Xilio Therapeutics (XLO) Current Assets (2020 - 2026)
Xilio Therapeutics (XLO) posted Current Assets of $154.2 million for Q1 2026, up 6.33% sequentially from $145.0 million in Q4 2025, and up 65.46% YoY from $93.2 million in Q1 2025.
Xilio Therapeutics (XLO) Current Assets (2020 - 2026) Analysis & Trends
Xilio Therapeutics has reported Current Assets for 7 years, with the latest figure at $154.2 million in Q1 2026.
- Quarterly Current Assets rose 65.46% year-over-year to $154.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $154.2 million (up 65.46% YoY) and the FY2025 annual result came in at $145.0 million, up 140.77% from the prior year.
- Current Assets rose to $154.2 million in Q1 2026 per XLO's latest filing, from $145.0 million in the prior quarter.
- Over five years, Current Assets peaked at $181.1 million in Q1 2022 and troughed at $48.1 million in Q4 2023.
- A 5-year average of $106.5 million and a median of $97.0 million in 2023 frame the typical range for Current Assets.
- The sharpest annual moves came in 2023 and 2025: Current Assets sank 61.34% in 2023, then soared 140.77% in 2025.
- Over 5 years, Current Assets stood at $124.5 million in 2022, then tumbled by 61.34% to $48.1 million in 2023, then advanced by 25.16% to $60.2 million in 2024, then jumped by 140.77% to $145.0 million in 2025, then climbed by 6.33% to $154.2 million in 2026.
- According to Business Quant data, Current Assets over the past three periods registered $154.2 million, $145.0 million, and $124.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.62 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.63 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 1.76 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 18.80 Bn |
| 10 | Xilio Therapeutics | 177.75 Mn | 41.71 Mn | - | 145.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 145.47 Mn |
| Mar 31, 2026 | 154.21 Mn |
| Dec 31, 2025 | 145.03 Mn |
| Sep 30, 2025 | 124.09 Mn |
| Jun 30, 2025 | 123.72 Mn |
| Mar 31, 2025 | 93.20 Mn |
| Dec 31, 2024 | 60.23 Mn |
| Sep 30, 2024 | 63.31 Mn |
| Jun 30, 2024 | 78.01 Mn |
| Mar 31, 2024 | 69.19 Mn |
| Dec 31, 2023 | 48.13 Mn |
| Sep 30, 2023 | 64.48 Mn |
| Jun 30, 2023 | 78.43 Mn |
| Mar 31, 2023 | 96.98 Mn |
| Dec 31, 2022 | 124.50 Mn |
| Sep 30, 2022 | 142.31 Mn |
| Jun 30, 2022 | 163.01 Mn |
| Mar 31, 2022 | 181.09 Mn |
| Dec 31, 2021 | 202.52 Mn |
| Sep 30, 2021 | 105.57 Mn |